The volume of healthcare deals has increased in 2022, driven in large part by private equity, according to a new PwC report. But deal values have been declining, a trend that is expected to continue into 2023.
For small biotech companies that are always raising money, business development is a critical next step. Joining with a credible partner goes a long way in validating technology and platforms and gives small biotech companies the runway needed to grow.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In 2021 biotech had a median deal of $10 million and an average deal of $36.9 million, according to the report by PitchBook Data. Comparatively, medtech locked in an median of $3.9 million and $12.6 million average.
After a relatively slow 2016 for life sciences deals...
Last year proved a slow one for dealmaking in the life sciences space. But that didn’t stop two of the major legal players in it from consummating one themselves: In November, Arnold & Porter and Kaye Scholer agreed to merge, bringing together two formidable healthcare practices.